Astellas

News

Astellas taps GO's glycoprotein platform with $783.5m deal

Astellas has become the latest big pharma company to sink some money into immuno-oncology start-up GO Therapeutics, forging an alliance to develop antibodies targeting two glycoprotein targ

News

Astellas takes $170m charge as it drops DMD gene therapies

Astellas has said it will book a $170 million impairment charge in its fourth quarter results as a result of a decision to halt the development of three gene therapy candidates for Duchenne

R&D

Inside the changing tides of life science research

Astellas Pharma chief medical officer Bernhardt Zeiher talks about the evolution of R&D in life sciences

News

Mature Woman Experiencing Hot Flush From Menopause

Astellas' eyes filings for menopause drug fezolinetant after...

Astellas looks to be in pole position to bring a new non-hormonal therapy for symptoms of menopause to market, after its candidate fezolinetant cleared a phase 3 safety study.

News

Trial win sets up new use for Astellas, Seagen's Padcev in b...

Astellas and Seagen's Padcev is on course to move further up the treatment pathway in bladder cancer, thanks to a positive readout in the EV-103 clinical trial.

News

Astellas says Pompe gene therapy clears safety hurdle

With the safety of gene therapies thrown into the spotlight by a series of FDA clinical holds, Astellas has said that an interim readout in a phase 1/2 trial of its Pompe disease candidate

Astellas taps GO's glycoprotein platform with $783.5m deal

Astellas takes $170m charge as it drops DMD gene therapies

Inside the changing tides of life science research

Astellas' eyes filings for menopause drug fezolinetant after...

Trial win sets up new use for Astellas, Seagen's Padcev in b...

Astellas says Pompe gene therapy clears safety hurdle

Praxis soars on rare childhood epilepsy trial data

How to meet your physicians where they are online

Astellas

Editor's Picks